Mobile website
Expert Forum
Industrialization prospect of CD19-CAR-T cell therapy technology
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
The chimeric antigen receptor gene-modified T cells (CAR-T) technique has constantly made breakthroughs in clinical practice since 2010, especially in the treatment of refractory, relapsed B cell-derived hematologic malignancies (such as acute lymphoblastic leukemia, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma), targeting CD19 molecule of the CAR-T has obtained clinical efficacy which has never been achieved by traditional tumor therapy strategies, and become the most attractive area of the moment in cancer immunotherapy. However, high recurrence rate, toxic side effects and expensive preparation costs of CAR-T, which appeared constantly in the CAR-T cell therapy, have also brought uncertainties to the industrialization of this technique. The article summarized the current development situation of CAR-T cell therapy technique in leading enterprises of the world and thoroughly analyzed challenges to the development of this technique industrialization, as well as evaluated development trend and industrialization prospect of this technique.
Keywords:
Project Supported:
Project supported by the Collaborative Innovation Major Project (No. XYXT2015304), and the Major R & D Project of Shandong Province (No.2015GSF118108)
Clc Number:
